Charco Neurotech has developed a wearable device called the CUE1 that shows promise in reducing the symptoms of Parkinson's disease. The CUE1 is a noninvasive and affordable solution that utilizes cueing to alleviate tremors, rigidity, and freezing of gait.
Charco Neurotech's CUE1: Revolutionizing Parkinson's Disease Treatment
( Credit to: Wired )
In 2015, Lucy Yung, an industrial designer specializing in assistive devices for individuals with motor control difficulties, faced a new perspective when she was diagnosed with a brain tumor. This personal experience reinforced her belief in the transformative power of support and assistance for individuals with long-term conditions. After recovering, Yung focused on improving the lives of those with Parkinson's disease.
Parkinson's disease is characterized by a communication problem within the brain, resulting from damage to neurons in the substantia nigra. This damage leads to a decrease in dopamine levels and abnormal electrical rhythms, causing tremors, rigidity, and freezing of gait.
Charco Neurotech, founded by Lucy Yung in 2019, has developed the CUE1, a wearable device that shows promise in reducing the symptoms of Parkinson's disease. This innovative device utilizes cueing, a rhythmic auditory, visual, or physical stimulation, to help individuals with Parkinson's walk more fluidly.
Noninvasive and Affordable: The CUE1 Advantage
The CUE1 distinguishes itself from deep-brain stimulation implants by being noninvasive and easy to use. It attaches to the wearer's sternum using medical adhesive, eliminating the need for surgery or invasive procedures. This makes it a more accessible and affordable option for individuals with Parkinson's disease.
Additionally, the CUE1 is priced at £295 ($371), making it an affordable solution compared to other treatment options. Its affordability and ease of use have made it a popular choice among individuals with Parkinson's disease.
Personalized Cueing with the CUE1
To enhance the user experience, the CUE1 comes with an accompanying app that allows users to personalize the device's vibration pattern. This customization ensures that each individual receives the most effective cueing pattern for their specific needs. In the future, Charco Neurotech envisions developing a feedback system that automatically adjusts the cueing pattern based on the individual's movement, further optimizing the device's effectiveness.
Users have reported using the CUE1 throughout the day, and some even find it beneficial for sleep quality, using it during sleep. The device's versatility and personalized cueing make it a valuable tool in managing Parkinson's disease symptoms.
Charco Neurotech: Making a Global Impact
Charco Neurotech's CUE1 device has gained significant traction worldwide. Currently, over 2,000 individuals in the UK are using the CUE1, with a waiting list of nearly 20,000 across 120 countries. The device's effectiveness and affordability have made it a sought-after solution for individuals living with Parkinson's disease.
Charco Neurotech's success has been supported by more than $10 million in funding and grants. This financial backing has allowed the company to employ a team of 38 individuals, including Parkinson's specialists, nurses, engineers, and data analysts. Their collective efforts aim to obtain regulatory approval for the device, making it accessible through the National Health Service or Medicaid.
The Future of Parkinson's Disease Treatment
With ongoing research and development, Charco Neurotech's CUE1 device has the potential to improve the quality of life for countless individuals affected by Parkinson's disease. Its noninvasive nature, affordability, and personalized cueing make it a promising solution for managing symptoms and enhancing mobility.
As Charco Neurotech continues to innovate and expand its reach, the CUE1 offers hope to Parkinson's patients worldwide. This wearable device is not only transforming treatment options but also providing a sense of empowerment and independence to those living with Parkinson's disease.